Trial Type
Follow-Up Treatment (Metastatic Disease)
Description for experts
The purpose of this platform study is to evaluate the safety, tolerability,pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitorscombined with Standard(s) of Care (SOC) or with each other.The first two subprotocols include the following:Subprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC
Description for laymen
The objective of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of novel RAS(ON) inhibitors in combination with standard(s) of care (SOC) or with each other. The first two sub-protocols include the following: Subprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC
JSON Data
{
"short_title": "RMC-Lung-101: ",
"data_mode": "900",
"data_mode_number": "000002374",
"official_title": " A Platform Study of RAS(ON) Inhibitor Combinations in Patients with RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)",
"accrual_state": "running",
"therapeutic_value": "therapeutic",
"therapieansatz_value": "palliativ",
"therapieintervention_value": "not_applicable",
"therapielinie_value": "gtThird",
"ctgov_number": "NCT06162221",
"eudract_number": null,
"general_contact_email": "ectu@ukdd.de",
"general_contact_phone": "+49 351-4587566",
"hauptpruefer_dd_name": "Prof. Dr. med. habil Martin Wermke",
"description_laie_de": "Ziel dieser Plattformstudie ist es, die Sicherheit, Vertr\u00e4glichkeit, Pharmakokinetik (PK) und vorl\u00e4ufige Antitumoraktivit\u00e4t neuartiger RAS(ON)-Inhibitoren in Kombination mit Standard(s) of Care (SOC) oder miteinander zu untersuchen. Die ersten beiden Unterprotokolle umfassen Folgendes: Unterprotokoll A: RMC-6291 + SOC Unterprotokoll B: RMC-6236 + SOC",
"description_laie_en": "The objective of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of novel RAS(ON) inhibitors in combination with standard(s) of care (SOC) or with each other. The first two sub-protocols include the following: Subprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC",
"description_expert_de": "Ziel dieser Plattformstudie ist es, die Sicherheit, Vertr\u00e4glichkeit, Pharmakokinetik (PK) und vorl\u00e4ufige Antitumoraktivit\u00e4t neuartiger RAS(ON)-Inhibitoren in Kombination mit Standard(s) of Care (SOC) oder miteinander zu untersuchen. Die ersten beiden Unterprotokolle umfassen Folgendes: Unterprotokoll A: RMC-6291 + SOC Unterprotokoll B: RMC-6236 + SOC",
"description_expert_en": "The purpose of this platform study is to evaluate the safety, tolerability,pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitorscombined with Standard(s) of Care (SOC) or with each other.The first two subprotocols include the following:Subprotocol A: RMC-6291 + SOC Subprotocol B: RMC-6236 + SOC",
"rechtsgrundlage_value": "AMG",
"phase_amg_value": "I_II",
"main_cat_id": 10,
"sub_cat_id": 50
}
